Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
HIK Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HIK Stock 12 Month Forecast
Average Price Target
2,480.83p
▲(17.46%Upside)
| Highest Price Target2,650p | Average Price Target2,481p | Lowest Price Target2,000p |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
2,345p
Buy
11.03%
Upside
Reiterated
05/16/25
Hikma Pharmaceuticals is positioned well with strong financial health and strategic corporate actions supporting its outlook. The stock's valuation is reasonable, providing a good entry point for long-term investors. However, technical analysis suggests cautious optimism due to current market momentum challenges. The overall score reflects the company's robust financial foundation, strategic initiatives, and reasonable valuation, balanced by technical market conditions.
RBC Capital
2,525p→2,625p
Buy
24.29%
Upside
Reiterated
05/20/25
Exane BNP Paribas
2,650p
Buy
25.47%
Upside
Initiated
05/14/25
Stifel Nicolaus
2,650p
Buy
25.47%
Upside
Reiterated
04/24/25
Jefferies
2,090p→2,400p
Buy
13.64%
Upside
Upgraded
04/10/25
Berenberg Bank
2,560p
Buy
21.21%
Upside
Reiterated
03/11/25
J.P. Morgan
―
Buy
―
Reiterated
03/07/25
Morgan Stanley
2,100p→2,400p
Hold
13.64%
Upside
Reiterated
02/12/25
Deutsche Bank
2,750p→3,100p
Buy
46.78%
Upside
Reiterated
11/25/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
2,345p
Buy
11.03%
Upside
Reiterated
05/16/25
Hikma Pharmaceuticals is positioned well with strong financial health and strategic corporate actions supporting its outlook. The stock's valuation is reasonable, providing a good entry point for long-term investors. However, technical analysis suggests cautious optimism due to current market momentum challenges. The overall score reflects the company's robust financial foundation, strategic initiatives, and reasonable valuation, balanced by technical market conditions.
RBC Capital
2,525p→2,625p
Buy
24.29%
Upside
Reiterated
05/20/25
Exane BNP Paribas
2,650p
Buy
25.47%
Upside
Initiated
05/14/25
Stifel Nicolaus
2,650p
Buy
25.47%
Upside
Reiterated
04/24/25
Jefferies
2,090p→2,400p
Buy
13.64%
Upside
Upgraded
04/10/25
Berenberg Bank
2,560p
Buy
21.21%
Upside
Reiterated
03/11/25
J.P. Morgan
―
Buy
―
Reiterated
03/07/25
Morgan Stanley
2,100p→2,400p
Hold
13.64%
Upside
Reiterated
02/12/25
Deutsche Bank
2,750p→3,100p
Buy
46.78%
Upside
Reiterated
11/25/24
Best Analysts Covering Hikma Pharmaceuticals
1 Month
xxx
Success Rate
9/12 ratings generated profit
Average Return
+4.08%
upgraded a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.08% per trade.
3 Months
xxx
Success Rate
6/12 ratings generated profit
Average Return
+1.42%
upgraded a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.42% per trade.
1 Year
Success Rate
4/7 ratings generated profit
Average Return
+0.79%
reiterated a buy rating last month
Copying Christian Glennie's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +0.79% per trade.
2 Years
xxx
Success Rate
10/17 ratings generated profit
Average Return
+4.54%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +4.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HIK Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
5
6
7
8
7
Hold
2
3
2
3
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
9
9
11
8
Each month's total comprises the sum of three months' worth of ratings.
HIK Financial Forecast
HIK Stock Forecast FAQ
What is GB:HIK’s average 12-month price target, according to analysts?
Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,480.83.
What is GB:HIK’s upside potential, based on the analysts’ average price target?
Hikma Pharmaceuticals PLC has 17.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?
Hikma Pharmaceuticals PLC has a consensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Hikma Pharmaceuticals PLC’s share price target?
The average share price target for Hikma Pharmaceuticals PLC is 2,480.83. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,650.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 17.46% Increase from the current price of 2,112p.
The highest analyst share price target is 2,650.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 17.46% Increase from the current price of 2,112p.
What do analysts say about Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of Hikma Pharmaceuticals PLC?
To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.